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Abstract
Fifty-seven type 2 diabetic patients with metabolic syndrome and on
insulin were assessed by a paired analysis before and 6 months after
addition of metformin as combination therapy to evaluate the impact
of the association on glycemic control, blood pressure, and lipid
profile. This was a historical cohort study in which the files of type 2
diabetic patients with metabolic syndrome on insulin were reviewed.
The body mass index (BMI), waist circumference, lipid profile, A1C
level, fasting blood glucose level, daily dose of NPH insulin, systolic
blood pressure, and diastolic blood pressure were assessed in each
patient before the start of metformin and 6 months after the initiation
of combination therapy. Glycemic control significantly improved (P <
0.001) after the addition of metformin (1404.4 ± 565.5 mg/day), with
14% of the 57 patients reaching A1C levels up to 7%, and 53%
reaching values up to 8%. There was a statistically significant reduc-
tion (P < 0.05) of total cholesterol (229.0 ± 29.5 to 214.2 ± 25.0 mg/
dL), BMI (30.7 ± 5.4 to 29.0 ± 4.0 kg/m2), waist circumference (124.6
± 11.7 to 117.3 ± 9.3 cm), and daily necessity of insulin. The reduction
of total cholesterol occurred independently of the reductions of A1C
(9.65 ± 1.03 to 8.18 ± 1.01%) and BMI and the reduction of BMI and
WC did not interfere with the improvement of A1C. In conclusion, our
study showed the efficacy of the administration of metformin and
insulin simultaneously without negative effects. No changes were
detected in HDL-cholesterol or blood pressure.
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Introduction
The need for strict glycemic control in
order to avoid or postpone the development
of late complications in patients with type 2
diabetes mellitus (DM2) has been well es-
tablished (1). It has been shown that the
onset of complications may be related to
glycosylated hemoglobin (A1C) levels higher
than 7%, a situation that is even more likely
if glycemic control is poor, with A1C levels
above 8% (2). Although the initial manage-
ment of DM2 involves lifestyle changes and
oral hypoglycemic drugs, a significant num-
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ber of patients will need insulin in order to
reach satisfactory glycemic control (3). Fur-
thermore, DM2 does not mean glycemic
alterations alone since this disease is associ-
ated with cardiovascular risk factors such as
dyslipidemia, systemic arterial hypertension,
and obesity (4). This association is clinically
relevant since over 50% of deaths among
DM2 patients are due to cardiovascular dis-
ease (5).
Treatment of DM2 must include pharma-
cological agents able to improve not only
glycemic levels, but also blood pressure (BP),
lipid levels, and body weight, since in ap-
proximately 90% of type 2 diabetics hyper-
glycemia is associated with other cardiovas-
cular factors that constitute the metabolic
syndrome.
Several studies (6,7) have demonstrated
that, in order to prevent the development and
progression of chronic complications of dia-
betes, a comprehensive approach to all ele-
ments of the metabolic syndrome is required.
The main feature of the metabolic syndrome,
which can be clinically assessed by measure-
ment of the waist circumference (WC) when-
ever more sophisticated laboratory methods
are not available (8), is insulin resistance.
After metformin proved to be effective in
reducing insulin resistance (9), several stud-
ies were undertaken to assess its effects on
total cholesterol (TC), triglycerides (TG),
and HDL-cholesterol (HDL-C) levels, and
also on BP and body mass index (BMI).
However, there is no consensus about its
beneficial effects on these parameters (10).
Most studies have analyzed independent
samples, comparing patients on insulin with
patients on combined insulin-metformin
therapy (11-13) with no conclusive results.
The objective of the present study was to
assess a group of DM2 patients with meta-
bolic syndrome, on insulin, before and 6
months after the introduction of metformin
as combined therapy, so as to evaluate the
effect of this association on glycemic con-
trol, BP, and the lipid profile.
Patients, Material and Methods
Data collection
We undertook a historical cohort study
by assessing the medical files of type 2
diabetic patients with metabolic syndrome,
on insulin, seen at a public diabetes-dedi-
cated facility in a medium-sized Brazilian
city (Juiz de Fora). All patients were fol-
lowed up bimonthly by a team composed of
four endocrinologists, a nutritionist, and a
diabetes-trained nurse.
Patient selection
We selected files of patients who had
been on twice daily injections of NPH insu-
lin and who had metformin added to their
therapy. Any file that showed any dietary
indiscretion or drug misuse was not utilized
in the study. A dietary indiscretion was de-
fined as the intake of sucrose-containing
foods three or more times a week, not con-
sidering the use of sweet foods taken during
hypoglycemic episodes. A drug misuse was
defined as any failure to take the prescribed
drugs, as reported by the patient.
To avoid the inclusion of late-onset type
1 DM patients in the sample, we studied only
patients with documented control of their
disease with oral hypoglycemic drugs alone
for at least 5 years before they began insulin
treatment, and who showed no evidence of
previous episodes of ketoacidosis. All pa-
tients followed the same diet, prescribed and
monitored by the nutritionist.
The patients were diagnosed as having
metabolic syndrome if they fulfilled at least
3 of the National Cholesterol Education Pro-
gram - Adult Treatment Panel III (NCEP
ATP III) criteria (14). Although other crite-
ria exist, as the World Health Organization
criteria, the NCEP ATP III was the most
widely used classification at present (6).
All patients had type 2 diabetes mellitus
(blood glucose >126 mg/dL), high triglycer-
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ide levels (>150 mg/dL), and increased WC
(women: >88 cm; men: >102 cm). Table 1
shows the patients’ characteristics.
A patient on anti-hypertensive or lipid-
lowering drugs was only included if there
was no change in the dosages of these drugs
throughout the study period. Full attendance
of scheduled consultations was another in-
clusion criterion.
Variables studied
BMI, WC, lipid profile (TC, HDL-C, and
TG), A1C, fasting blood glucose (FBG),
daily dose of NPH insulin, systolic blood
pressure (SBP), and diastolic blood pressure
(DBP) were measured in each patient before
the start of metformin and 6 months after
initiation of combined therapy.
Weight measurements were made only
once, with a digital scale with a maximum
capacity of 180 kg and precision of up to 100
g. The patients were weighed in their under-
wear after carefully stepping onto the center
of the scale.
Height was measured only once, with a
1-mm precision tape measure fixed to the
wall, with the zero mark at floor level. The
patients were standing, with bare feet kept
together, and with heels and occiput touch-
ing the tape.
For WC measurement, the patients were
standing, with abdomen relaxed, upper limbs
falling along the body, and the tape placed
horizontally, halfway between the lower
margin of the last rib and the iliac crest; the
measurements were made with the tape firmly
applied to the pelvis but without tissue com-
pression. A flexible 1-mm precision tape
measure was used.
Blood pressure was measured three times
within a 10-min interval on the left arm, with
the patient in the supine position, after a 5-
min rest, with a calibrated mercury sphyg-
momanometer.
TC, HDL-C, TG, and FBG levels were
measured by the colorimetric method, with
maximum acceptable values of 240 mg/dL
(TC), 200 mg/dL (TG), and 110 mg/dL
(FBG). The minimum acceptable value for
HDL-C was 35 mg/dL. A1C was measured
by high-performance liquid chromatogra-
phy (normal reference for stable A1C in
non-diabetic patients is 2.8 to 5.2%, accord-
ing to the National Glycohemoglobin Stan-
dardization Program). All laboratory deter-
minations were performed automatically. The
study was approved by the local Ethics Com-
mittee and all patients signed written in-
formed consent.
Statistical analysis
The data are reported as means ± SD,
percentages (%) or 95% confidence inter-
vals (95% CI). All tests were two-tailed, and
the level of significance was set at P < 5%.
In order to compare the means of the
study variables before and after the intro-
duction of metformin, a paired t-test with
95% CI of the means was used. If the t-test
showed a difference for any variable stud-
ied, Pearson’s correlation test was performed
to check for possible intervening variables
(co-variance) by the analysis of the coeffi-
cient of determination (r 2) and r 95% CI. All
assumptions for the undertaking of paramet-
ric tests were checked and accounted for.
The statistical package GraphPad InStat,
version 3.06, for Windows (San Diego, CA,
USA) was used in the analyses.
Table 1. Characteristics of the cohort.
Demographics
N   57
Age (years) 58.9 ± 8.0
Duration of diabetes (years) 15.9 ± 5.7
Daily metformin dose (mg) 1404.4 ± 565.5
Sex (male/female)   26/31
Concomitant medication
Lipid-lowering drugs   18 (31)
Blood pressure-lowering drugs   32 (56)
Data are reported as means ± SD or N (%).
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Results
Fifty-seven files met the inclusion crite-
ria and were analyzed in this study.
There was a statistically significant re-
duction of the daily dose of NPH insulin, of
BMI, WC and TC, and TG levels when the
values before and 6 months after metformin
were compared. Neither BP (SBP or DBP),
nor HDL-C suffered any alteration. Table 2
summarizes the comparative measurements.
Glycemic control improved significantly
(P < 0.0001) after the introduction of met-
formin, with a reduction of mean FBG and
A1C levels (Table 2). Furthermore, 14% of
the patients reached A1C levels of up to 7%,
53% had A1C values of up to 8%, and 47%
had unsatisfactory glycemic control. Before
metformin introduction, all patients had A1C
>8%. Correlation tests showed that TC re-
duction was independent of reductions in
A1C, WC, and BMI. Reduction of BMI and
WC also did not interfere with glycemic
control. However, a slight correlation was
seen between reduction of TG and BMI (r2 =
12.5%), and TG and WC (r2 = 8%), suggest-
ing a certain degree of co-variance. The
correlations calculated can be analyzed by
the determination coefficients and 95% CI
shown in Table 3.
None of the files showed reports of se-
vere hypoglycemia, i.e., a situation needing
somebody’s help. Although there were 16
reports (28% of the sample) of transient,
mild gastrointestinal upset (dyspepsia) at the
beginning of metformin use, there was no
necessity of dose reduction or withdrawal.
Anti-hypertensive drugs were hydrochlo-
rothiazide, propranolol, and captopril. Pa-
tients with dyslipidemia used lovastatin and
gemfibrozil. These drugs probably did not
interfere with the results, as there was no
alteration in dose or type of drug used
throughout the study period.
Discussion
Glycemic control
The present study showed that the addi-
tion of metformin to a scheme of NPH insu-
lin administered twice daily improved gly-
cemic control of type 2 diabetic patients
with the metabolic syndrome after 6 months,
regardless of BMI reduction, as already
shown in other studies (11,12). Although
one study showed that metformin can lead to
WC reduction (15), the improvement of A1C
levels in our sample was independent of WC
reduction, indicating that metformin im-
proves sensitivity to the action of insulin by
mechanisms already described, such as inhi-
bition of hepatic gluconeogenesis (16). Al-
Table 3. Pearson’s correlation test applied to pairs of variables.
Variables P value r 95% CI r2
TC and A1C 0.597 -0.072 -0.326 to 0.193 0.5%
TC and BMI 0.237 0.159 -0.106 to 0.403 2.5%
TC and WC 0.555 0.079 -0.185 to 0.334 0.6%
TG and A1C 0.605 0.070 -0.194 to 0.325 0.5%
TG and BMI* 0.007 0.354   0.102 to 0.562 12.5%
TG and WC* 0.033 0.282   0.023 to 0.505 8%
A1C and BMI 0.056 0.254 -0.007 to 0.483 6.4%
A1C and WC 0.926 0.012 -0.272 to 0.249 0.01%
TC = total cholesterol; A1C = glycohemoglobin level; BMI = body mass index; WC =
waist circumference; TG = triglycerides; r = correlation coefficient; r 2 = coefficient of
determination. *P < 0.05.
Table 2. Comparison of clinical and laboratory variables before and 6 months after the
introduction of metformin.
Before After     95% CI
A1C (%) 9.65 ± 1.03 8.18 ± 1.01*  1.09 to 1.86
FBG (mg/dL) 215.3 ± 28.0 167.2 ± 27.3*  37.5 to 58.6
Daily insulin dose (IU kg-1 day-1) 0.83 ± 0.39 0.69 ± 0.36*  0.02 to 0.26
BMI (kg/m2) 30.7 ± 5.4 29.0 ± 4.0* 0.1 to 3.3
Waist circumference (cm) 124.6 ± 11.7 117.3 ± 9.3* 3.6 to 10.9
Total cholesterol (mg/dL) 229.0 ± 29.5 214.2 ± 25.0* 4.9 to 24.7
HDL cholesterol (mg/dL) 37.5 ± 8.4 38.0 ± 6.3 -3.4 to 2.3
Triglycerides (mg/dL) 236.2 ± 40.2 218.5 ± 42.4* 1.5 to 34.0
Systolic blood pressure (mmHg) 158 ± 25 156 ± 18 -7 to 11
Diastolic blood pressure (mmHg) 92 ± 11 90 ± 14 -3 to 6
Data are reported as means ± SD. A1C = glycohemoglobin level; FBG = fasting blood
glucose. *P < 0.05 compared to before metformin treatment (Student t-test).
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though over half the patients reached A1C
levels below 8%, only 14% reached ideal
metabolic control (A1C up to 7%), and 47%
kept their A1C above 8%. More intensive
insulin therapy with fast-acting insulins and
self-monitoring might have led to better re-
sults (17). The mean FBG and A1C values of
our patients were similar to those reported in
other studies (11-13), although most studies
did not report the percentage of patients who
reached the established cut-off points for
A1C. Such information would have shed
light on the extent of glycemic control
reached at other centers, since the mean
value is sensitive to extreme values.
Lipid profile
The literature shows discrepant results
about the influence of metformin on lipid
profile (10). Some studies, in agreement with
ours, reported reduction only in TC levels
(18,19), while others reported reduction of
TC and TG with an increase of HDL-C
(20,21). Still other studies showed no changes
in lipid profile (22,23). Another investiga-
tion showed an association of metformin
with an improvement in the lipid profile
even in non-diabetic patients (24). New stud-
ies are needed to clarify this issue, since TG
and HDL-C are very important parameters
for the evaluation of metabolic syndrome.
A possible reason for these discrepant
results may be that the clinical studies cited
above analyzed data from independent
samples. In our study, this problem was
avoided by paired data analysis, in which
each patient was his own control, thereby
increasing the power of the statistical analy-
sis.
A recent meta-analysis (10) covering 41
studies on the effects of metformin on BP
and lipid profile showed that only TC reduc-
tion was significant. Our results are in agree-
ment with these findings and show that this
fact was independent of BMI and WC reduc-
tion. Since the TG reduction found in the
present study underwent interference from
BMI and WC (intervening variables), we
cannot conclude that metformin had a direct
and isolated effect on TG levels.
Other parameters
The fact that metformin did not reduce
BP in our sample agrees with other studies
(10,22,23,25), although there are reports of
SBP and DBP reduction with this drug
(26,27). A possible explanation for this dis-
crepancy may be the fact that not all patients
who lose weight experience reductions in
their plasma renin and aldosterone levels
(28,29). However, metformin is known to
positively affect other parameters which in-
fluence the development of cardiovascular
disease, regardless of any effect on BP (30,
31). Our results agree with the literature
regarding the effect of metformin on BMI
reduction (9,12,13), reduction of daily insu-
lin dose (9,12,13), biguanide-related side-
effects (21,24), and reduction of WC, which
is a cornerstone for the diagnosis of meta-
bolic syndrome and may play the role of a
co-variate when other parameters are ana-
lyzed (18,32).
In conclusion, our study showed the effi-
cacy of the administration of metformin and
insulin simultaneously without negative ef-
fects and no changes were detected in HDL-
cholesterol or blood pressure.
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